Vertebral osteomyelitis: Difference between revisions
From IDWiki
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
== |
== Background == |
||
===Microbiology=== |
|||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
*Other [[Gram-positive cocci]], including [[viridans group streptococci]], [[Streptococcus bovis]], [[enterococci]], [[Streptococcus agalactiae]], group C and G [[streptococci]] |
|||
*Less commonly, [[coagulase-negative staphylococci]], [[Gram-negative bacilli]], including [[Pseudomonas aeruginosa]], and [[Candida species]], especially in patients with indwelling lines or injection drug use |
|||
*[[Tuberculosis]] |
|||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
[[Category:Bone and joint infections]] |
[[Category:Bone and joint infections]] |
Revision as of 19:09, 13 October 2020
Background
Microbiology
- Staphylococcus aureus
- Other Gram-positive cocci, including viridans group streptococci, Streptococcus bovis, enterococci, Streptococcus agalactiae, group C and G streptococci
- Less commonly, coagulase-negative staphylococci, Gram-negative bacilli, including Pseudomonas aeruginosa, and Candida species, especially in patients with indwelling lines or injection drug use
- Tuberculosis
- Brucella, in patients from endemic countries, can be as high as 25% of cases
Management
- IV or highly bioavailable oral (metronidazole, fluoroquinolones, linezolid, TMP-SMX, clindamycin, and doxycycline/rifampin)
- Can double-cover Enterococcus with an aminoglycoside for 4 to 6 weeks
- Duration: 6 weeks for most, but 3 months for Brucella
Brucella
- Doxycycline/rifampin
- Duration: 3 months
Prognosis
- Cure rates are 70-90% with 6 weeks of antibiotics, and are not higher with longer durations (per a single RCT)
- Poor prognosis is associated with multidisc disease, the presence of concomitant epidural abscess, lack of surgical therapy, infection with S. aureus, old age, or the presence of significant comorbidities